Exclusive Summary

• - Mature low-osmolar, non-ionic contrast with long-expired patents; entry barrier lies in quality and supply reliability rather than IP.
• - 100 mL/350 mgI/mL matches the most common adult CT enhancement dose, aligning with global tender specifications.
• - ~400–450 million CT exams annually worldwide, ~50% requiring iodinated contrast, yielding 200M+ dose-level, 5–7% CAGR demand.
• - Multi-pharmacopoeia compliance (USP/EP/BP/JP/KP/Ph. Int.) enables multi-region registrations and supports tech transfer/local fill-finish.
• - Compared with originator, generics typically deliver 30–60% price savings, with further gains via TT and local manufacturing.